Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition
Open Access
- 15 December 2022
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 12 (1)
Abstract
New treatment options to battle hormone-refractory prostate carcinoma (PC) are a pressing medical need. Chronic inflammation has been implicated in PC etiology. The pro-inflammatory cytokines IL-6, IL-23 and IL-17 are key mediators to promote growth of PC. Here, we evaluate the potential of immunoproteasome inhibition for anti-inflammatory and direct anti-tumorigenic therapy of PC. The anti-tumor effect of immunoproteasome inhibitor ONX 0914 was tested in mouse and human PC cells and the in vivo therapeutic efficacy of immunoproteasome inhibition was analyzed in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice in preventive and therapeutic settings and in castration-resistant (CR)PC after castration. Inhibition of the immunoproteasome subunit LMP7 induced apoptotic cell death in PC cell lines. In TRAMP mice, ONX 0914-treatment resulted in significant inhibition of PC growth with a decreased frequency of malignant prostatic lesions and inhibition of metastasis formation. The number of immunosuppressive myeloid cells in PC was greatly reduced in response to ONX 0914. Thus, immunoproteasome inhibition shows remarkable efficacy against PC progression in vivo and impedes tumor recurrence in CRPC-TRAMP mice by blocking the immunosuppressive inflammatory response in the tumor microenvironment. In conclusion, we show that the immunoproteasome is a promising drug target for the treatment of PC.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (NA)
This publication has 52 references indexed in Scilit:
- Targeting the unfolded protein response in diseaseNature Reviews Drug Discovery, 2013
- Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progressionOncogene, 2013
- A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude miceBritish Journal of Cancer, 2012
- The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer MicroenvironmentCancer Cell, 2011
- IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor CellsThe Journal of Immunology, 2010
- Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patientsInternational Journal of Cancer, 2009
- Expression of catalytic proteasome subunits in the gut of patients with Crohn’s diseaseInternational Journal of Colorectal Disease, 2009
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg SkewingClinical Cancer Research, 2008
- Dissociation of Epithelial and Neuroendocrine Carcinoma Lineages in the Transgenic Adenocarcinoma of Mouse Prostate Model of Prostate CancerThe American Journal of Pathology, 2008
- MHC Class I Expression in Mice Lacking the Proteasome Subunit LMP-7Science, 1994